Program
KRAS G12D Inhibitor HRS-4642
Also written as “HRS-717 + HRS-4642+SHR-1316;”, “HRS-4642” and “HRS4642”.
In Jiangsu HengRui Medicine’s pipeline, KRAS G12D
. Its studies are mostly in Pancreatic Neoplasms, led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Nov 14, 20257 company-led studies, 7 open or runningNext primary completion: Feb 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 77 open or running | phase 3since Nov 14, 2025 | Sep 5, 2022 | Feb 2027phase 1 · NCT07906691 |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-4642
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2022First study: phase 1 study in Advanced KRAS G12D Mutant Solid TumorsFirst studyNCT05533463 · 102 enrolled · China
- Jul 22, 2024Phase 2 study in Advanced Solid TumorsNCT06520488 · 118 planned · China
- Nov 14, 2025Phase 3 study in KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line SettingNCT07232875 · 588 planned · China
- Dec 9, 2025Phase 2 study in Locally Advanced or Metastatic Pancreatic Cancer WithNCT07296341 · 60 planned · China
- Sep 2, 2026Phase 2 study in Pancreatic NeoplasmsNCT07806058 · 140 planned · China
- Oct 22, 2026Phase 3 study in Systemic Treatment-naïve Pancreatic CancerNCT07900789 · 825 planned · China
- Oct 25, 2026Phase 1 study in Pancreatic NeoplasmsNCT07906691 · 18 planned · China
Ahead
- Feb 2027Primary completion: phase 1 study in Pancreatic NeoplasmsNCT07906691
- Mar 2027Primary completion: phase 2 study in Advanced Solid TumorsNCT06520488
- Oct 2027Primary completion: phase 2 study in Locally Advanced or Metastatic Pancreatic Cancer WithNCT07296341
- Dec 31, 2028Primary completion: phase 2 study in Pancreatic NeoplasmsNCT07806058
TargetBeta
“KRAS G12D”the company's pipeline, read by Claude · source
“An inhibitor of the oncogenic KRAS substitution mutation G12D, with potential antineoplastic activity. Upon administration, KRAS G12D inhibitor HRS-4642 specifically targets and binds to KRAS G12D. This prevents KRAS G12D-mediated signaling and activation of downstream survival pathways. This lea…”NCIt, read by Claude
“An inhibitor of the oncogenic KRAS substitution mutation G12D, ”NCIt, by rule
Other programs on KRAS
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| sotorasibrule | Amgen | phase 3 | 28 |
| adagrasibrule | Bristol-Myers Squibb | phase 3 | 16 |
| olomorasib | Eli Lilly | phase 3 | 16 |
| divarasib | Hoffmann-La Roche | phase 3 | 13 |
| KRAS G12D Inhibitor VS-7375rule | Genfleet Therapeutics (Shanghai) | phase 3 | 12 |
| glecirasibrule | Allist Pharmaceuticals | phase 3 | 12 |
| calderasib | Merck | phase 3 | 12 |
| daraxonrasibrule | Revolution Medicines | phase 3 | 10 |
| garsorasibrule | InventisBio | phase 3 | 8 |
| zoldonrasibrule | Revolution Medicines | phase 3 | 6 |
| HRS-7058 | Jiangsu HengRui Medicine | phase 3 | 6 |
| opnurasibrule | Novartis | phase 3 | 5 |
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07906691Pancreatic Neoplasms · China | 1 | Not yet recruiting | Feb 2027 | 18 |
| NCT07900789Systemic Treatment-naïve Pancreatic Cancer · China | 3 | Not yet recruiting | Nov 30, 2030 | 825 |
| NCT07806058Pancreatic Neoplasms · China | 2 | Recruiting | Dec 31, 2028 | 140 |
| NCT07296341Locally Advanced or Metastatic Pancreatic Cancer With · China | 2 | Recruiting | Oct 2027 | 60 |
| NCT07232875KRAS G12D-Mutant Advanced or Metastatic Pancreatic Cancer in the First-line Setting · China | 3 | Recruiting | Apr 2029 | 588 |
| NCT06520488Advanced Solid Tumors · China | 2 | Recruiting | Mar 2027 | 118 |
| NCT05533463Advanced KRAS G12D Mutant Solid Tumors · China | 1 | Active, not recruiting | Jun 25, 2024 | 102 |
How it is read
Names in the registry
- “HRS-717 + HRS-4642+SHR-1316;”, 3 entries
- “HRS-4642”, 2 entries
- “HRS4642”, 1 entry
- “HRS -4642 + SHR-1316+ Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection”, 1 entry
- “HRS -4642 + Gemcitabine Hydrochloride for Injection+Paclitaxel for Injection”, 1 entry
Conditions, from the studies’ own filings
- Pancreatic Neoplasms, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.